` LTRN (Lantern Pharma Inc.) vs S&P 500 Comparison - Alpha Spread

LTRN
vs
S&P 500

Over the past 12 months, LTRN has underperformed S&P 500, delivering a return of -19% compared to the S&P 500's 10% growth.

Stocks Performance
LTRN vs S&P 500

Loading
LTRN
S&P 500
Add Stock

Performance Gap
LTRN vs S&P 500

Performance Gap Between LTRN and GSPC
HIDDEN
Show

Performance By Year
LTRN vs S&P 500

Loading
LTRN
S&P 500
Add Stock

Competitors Performance
Lantern Pharma Inc. vs Peers

S&P 500
LTRN
ABBV
AMGN
GILD
VRTX
Add Stock

Lantern Pharma Inc.
Glance View

Market Cap
34.3m USD
Industry
Biotechnology

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.

LTRN Intrinsic Value
HIDDEN
Show
Back to Top